Pathogenetically justified use in real clinical practice of vaginal estriol 0.5 mg in women of different ages

Research in recent decades has shown a steady increase in the average life expectancy of humans, and women in particular. Any epithelial tissue reacts to changes in the surrounding hormonal environment in a similar way, but none of them can compare with the epithelium of the vaginal vault and cervix in terms of the speed and clarity of reaction to hormones, primarily sex steroids. The urogenital tract is especially sensitive to a decrease in estrogen levels, and about half of all women, both in reproductive age and during hormonal changes, may experience symptoms associated with vulvovaginal atrophy, affecting sexual health and quality of life. Estriol is the main estrogen that specifically addresses problems caused by estrogen deficiency: dyspareunia, dryness and itching in the vagina and lower genitourinary tract, urinary disorders, moderate urinary incontinence, as well as recurrent vulvovaginitis and cystitis. According to international and Russian clinical guidelines, the prescription of 0.5 mg is pathogenetically justified with a high level of persuasiveness and reliability. Vulvovaginal dystrophy in women of different ages is a multidisciplinary problem at the intersection of gynecology, urology and dermatology, which can and should be solved to prevent more severe gynecological and urological pathologies.